Canopy Growth Corp: insider trades · United States · SEC (Form 4)

About Canopy Growth Corp

Canopy Growth Corp. (ticker CGC) is a Canadian cannabis company listed in the United States on the Nasdaq market, with its corporate headquarters in Smiths Falls, Ontario, Canada. For French-speaking investors, it is one of the best-known names in the global cannabis industry, positioned at the intersection of medical cannabis, adult-use cannabis, and consumer products. The company emerged in the 2010s as Canada moved toward legalization and then expanded through a mix of brand building, acquisitions, and international licensing. Canopy Growth’s business model is now organized around several complementary revenue streams. In Canada, it sells medical cannabis and, to a lesser extent, adult-use cannabis. Internationally, it serves medical patients in markets including Europe and Australia, with management highlighting activity in Germany, Poland, and Australia. Another important pillar is Storz & Bickel, the company’s vaporization-device business, which gives Canopy a more industrial, hardware-oriented exposure and a premium product platform. Its brand portfolio includes Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, alongside Storz & Bickel’s category-defining vaporization devices. From a competitive standpoint, Canopy Growth remains one of the most recognized cannabis companies in North America, but it is also a company in transition. The strategic emphasis has shifted toward simplifying the operating footprint, improving profitability, and strengthening the balance sheet. That matters because the cannabis sector has remained highly competitive, regulation-driven, and financially demanding. Canopy’s brand strength and global medical reach are meaningful assets, but the company must continue to manage pricing pressure, uneven consumer demand, and regulatory complexity across jurisdictions. Recent developments reinforce that balance-sheet repair and execution are the key investment themes. In 2025 and early 2026, Canopy Growth announced recapitalization steps, debt prepayments, and a new at-the-market equity program of up to US$200 million to enhance liquidity and financial flexibility. Its fiscal 2025 results showed improved Adjusted EBITDA and continued cost discipline, while management emphasized the integration of its medical cannabis operations into a single global platform. The company also reported that German medical cannabis performance benefited from a broader patient product portfolio. Overall, CGC remains a Nasdaq-listed cannabis exposure with recognizable brands and international reach, but the investment case is still centered on restructuring progress, margin recovery, and balance-sheet strength in the United States-listed capital market context.